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Introduction
Menorrhagia remains a common and significant cause of morbidity in premenopausal women in the UK. In the event of a failure of first-line medical treatment, various surgical options are available. Hysterectomy is associated with the possibility of major adverse events and has its own mortality. First-generation endometrial ablation techniques such as rollerball, transcervical resection of the endometrium (TCRE) and laser ablation have largely been superseded by a variety of ingenious equipment commonly referred to as second-generation ablation devices.
All these modalities share the concept of aiming to destroy the endometrium including the basalis layer and stop its re-growth. It was argued that they should be easier and safer to perform, have reduced morbidity and mortality, and be as effective as first-generation devices. Furthermore, they do not require general anaesthesia and thus are more suitable to the office environment. All these potential advantages were seen as factors that would result in less hysterectomies being performed and ultimately reduce the overall costs for the management of menorrhagia.
Over the past decade, a number of techniques were introduced, and since the previous review [1] many more have been added and some withdrawn! The first of the second-generation devices was the fluid-filled balloon 'Thermachoice 1'; this was followed by other balloon devices, the microwave-based technique microwave endometrial ablation (MEA), impedance radiofrequency and laser-based techniques, and others. Several of these devices have been evaluated by the National Institute of Clinical Excellence (Table 1) , and evidence of their safety and effectiveness presented, while others are yet to be evaluated. In this review, evidence on longterm effectiveness, suitability for ambulatory and outpatient setting, complications, cost-benefit, and impact on the health service of these techniques will be presented.
Patient selection and endometrial preparation
Most of the second-generation devices (Cavaterm, Thermachoice, Novasure, Cryoablation) require a relatively normal uterine cavity of a depth under 12 cm to enable the device to complete the treatment satisfactorily. Free fluid ablation (HydroThermAblator) and MEA can be performed when the uterine cavity is irregular, although complete septate or bicornuate uteri are contraindications to undertaking the procedures. In all instances it is recommended to confirm the correct placement of the devices in the cavity with ultrasound especially in a mal-positioned uterus. In the case of cryoablation, the treatment is carried out under ultrasound guidance.
Several studies have assessed second-generation ablation devices in women with submucous fibroids. Successful outcomes were reported in randomized controlled studies for Unlike with first-generation endometrial ablation techniques, endometrial thinning is not necessary with most second-generation devices. Several studies have confirmed that success and patient satisfaction are not affected by endometrial preparation [5, 6, 7 ]. The exceptions are hydrothermablation [8] and the endometrial laser intrauterine thermal therapy (ELITT) system, where pretreatment endometrial thinning with gonadotrophinreleasing hormone analogues was reported to lead to superior amenorrhoea rate (website http://www.lumenis. com/wt/page/press/2002).
Type of anaesthesia and location of surgery
All manufacturers state that their respective devices can be used in the outpatients or as a day-case and without the need for general anaesthesia; however, the evidence in the literature is variable. Thermachoice under conscious sedation, local or no anaesthesia has been reported [9] [10] [11] [12] 13 ]. In a prospective observational study [11] , patient-controlled sedation was reported to be safe and effective in alleviating pain and discomfort, and was well received by patients. A more recent study [12] evaluated the use of local anaesthesia only in the outpatient setting. The procedure was successfully completed in 94% women (n ¼ 53), 27% of whom required postoperative opiate for pain relief and 4% overnight stay; 67% of women were satisfied at six months. Marsh et al. [13 ] performed the procedure in 24 of 27 women (89%) without local anaesthesia or intravenous sedation safely and successfully without complications. The use of ibuprofen obviated the need for rescue analgesia and most women were discharged within 3 h of the treatment. Two studies evaluated the use of Thermachoice in community [14] and primary care [15] settings, and concluded that the procedure was well tolerated by patients and suitable for these settings.
Similarly, a randomized clinical trial comparing MEA treatment under local and general anaesthesia reported local anaesthesia to be acceptable to the majority of women, but almost one in 10 women needed conversion to general anaesthesia because of discomfort [16] . With this in mind, the authors concluded that this treatment remains a day-case rather than an outpatient procedure. The same group [17] reported minimal cost savings to the patient or health service from using MEA under local rather than general anaesthesia in a theatre setting and that in a clinic setting MEA has a similar cost to a theatrebased treatment once re-admissions for general anaesthesia treatments were considered.
In a small cohort of 40 patients [8] undergoing hydrothermablation, the anaesthetic regimen comprised of a combination of oral mefenamic acid and cervical/ paracervical block using lignocaine 1% and adrenalin 1 : 200 000. The authors reported successful completion of the treatment in all subjects with a median pain score of 6.4 during the procedure and 88% of women finding it acceptable. All women were discharged within 2 h and none was readmitted.
Techniques and their effectiveness
The following techniques and devices will be reviewed in detail.
Balloon thermal ablations
Fluid-filled balloons were one of the earliest secondgeneration devices. In this section, three widely available devices will be reviewed. A fourth device, MenoTreat (Lina-Medical, Glostrup, Denmark) has been used in Finland and Sweden, but to the author's best knowledge very infrequently elsewhere. Two randomized controlled studies were published. There was no difference in the amenorrhoea rate between Cavaterm and TCRE, and a significantly shorter operating time for the Cavaterm. At 2 years follow-up, bleeding and pain recurrence were significantly higher with TCRE, while satisfaction and reoperation rates were higher with Cavaterm [18, 19] .
Thermachoice (Gynecare, Ethicon, Somerville, New Jersey, USA)
With Thermachoice, a balloon catheter is inserted into the uterine cavity and inflated with 5% dextrose solution to a pressure of 160-180 mmHg. The solution is heated to 878C for 8 min. The single-use silicone or latex balloon catheter housing a heating element and two thermocouples is connected through an umbilical cable to an electronic controller device.
A large multicentre observational study [9] demonstrated that Thermachoice 1 led to a significant reduction in the severity and duration of menstrual flow and dysmenorrhoea. Fifteen percent of women were amenorrhoeic and 88% had reverted to eumenorrhoea or less by 12 months. In comparison with rollerball [10] and TCRE [20, 21] , Thermachoice 1 achieved comparable reduction in menstrual loss with the first-generation techniques. Long-term follow-up [22] showed that nearly seven of 10 women were cured of menorrhagia without additional intervention 5 years after ablation, and that hysterectomies were performed because of bleeding and/or pelvic pain; onethird of them were associated with fibroids. Additional evidence [23] showed that 4-6 years after Thermachoice 1, the probability of avoiding hysterectomy was 86% of all women. In the same study, of the women avoiding hysterectomy, 47% were amenorrhoeic, 30% were hypomenorrhoiec, 13.6% were eumenorrhoiec and only 8.5% had heavy periods.
Thermablate endometrial ablation (MDMI Technologies, Richmond, British Columbia, Canada)
In this technique a disposable cartridge consisting of a silicone balloon, catheter and reservoir is connected to the treatment control unit, and the fluid is heated in the reservoir to 1738C before the treatment commences. The temperature of the fluid in the balloon is approximately 1558C when it first enters the uterus and declines to approximately 1158C by the end of the 128-s treatment period. Once the balloon has been inserted into the uterine cavity and the user depresses the trigger button, a pneumatic pump applies pressure to the reservoir and fluid is forced into the balloon achieving a pressure of 180-200 mmHg. During treatment the pressure is pulsed periodically to mix the fluid within the balloon and ensure a uniform temperature distribution. Early reports [24, 25] Endometrial cryotherapy is a nonhysteroscopic technique that uses cold temperatures to freeze and destroy the endometrium. The cryoprobe is inserted into the uterus and a small amount of saline solution may be injected into the cavity to enhance freezing. The cryoprobe is cooled by perfusing it with either liquid nitrogen or a compressed gas mixture. The tip of the probe, where freezing occurs, is placed in one cornua of the uterus, and then moved to the other and the remainder of the uterine cavity in a series of freeze-thaw cycles. Ultrasound is used to monitor the position of the probe and depth of tissue freezing. Declared advantages over other techniques include (1) ease of use, (2) quick and safe to perform due to direct ultrasound visualization of the ablation depth, (3) requires less anaesthetic due to the analgesic effect of cold temperatures, and (4) potential for use in the outpatient setting.
Efficacy is based on the results of a randomized controlled trial with rollerball ablation [26, 27] . At 12 months, return to eumenorrhoea (pictorial blood loss assessment chart score 75 or below) was 67.4% in the cryoablation group and 73.3% following rollerball therapy, 27.6 and 55.5% had amenorrhoea, and 12% and 6.9% had continued menorrhagia (pictorial blood loss assessment chart score above 100) in the respective groups. At 24 months, patient satisfaction and improvement in quality of life was up to 91%. The two groups had similar and nonsignificantly different hysterectomy and re-treatment rates.
In addition to minor adverse events that occurred during and in the immediate postoperative period, late events within 12 months included severe abdominal cramping and vaginal pain, prolonged tiredness, and perimenopausal symptoms.
Free fluid endometrial ablation: HydroThermAblator (Boston Scientific, Natick, Massachusetts, USA)
guidance. The saline is heated to 908C and circulated for 10 min.
A randomized controlled trial comparing the Hydro ThermAblator with rollerball ablation [28, 29] Minor operative or postoperative complications were reported; however, more seriously, first-degree burns on the buttocks and upper thighs due to prolonged contact with tubing connecting the control unit to the inflow channel of the hysteroscopic sheath were reported as well. Since then, the design of the equipment was changed to avert such injury.
Impedance bipolar radiofrequency endometrial ablation: Novasure (Novacept, Palo Alto, California, USA)
In this technique a sheath containing a bipolar radiofrequency electrode is placed through the cervix into the normal shaped uterine cavity. The sheath is pulled back, allowing the unique gold-mesh electrode to expand and conform to the shape of the uterine cavity, and radiofrequency energy is then delivered into the uterus via the electrode. The treatment usually lasts for approximately 90 s, and the electrode is then retracted back into the sheath and removed from the uterus. Women with fibroids or large polyps inside the uterine cavity are unsuitable for this technique. No endometrial pretreatment is necessary.
Efficacy was reported in two randomized controlled trials [30, 31] and two case series studies. Amenorrhoea rates in these four studies ranged from 41 to 59% at 12 months, with higher amenorrhoea rates in the impedance controlled procedure. Continuing menorrhagia rates ranged from 3.9 to 14% at 12 months. There was also evidence to suggest that the majority of patients were satisfied following the procedure and that quality of life had improved. At 3-year follow-up [32] hysterectomy was avoided in 97% of women, 65% of whom were amenorrhoeic.
A similar but monopolar radiofrequency system was introduced in the mid-1990s called Vestablate and comprised of 12 thin, plate-like electrodes over a distensible balloon attached to an 8-mm catheter. The device is not available at present. MEA is another ingenious second-generation endometrial ablation device where low-power, high-frequency microwave energy is used to generate heat and destroy the endometrium. The probe is inserted into the uterine cavity and moved from side to side with the temperature maintained at 75-808C to destroy the endometrium.
In a well-designed randomized controlled trial, MEA was compared to TCRE [35] and was reported to have significantly shorter mean operative time than TCRE (11.4 versus 15.0 min, P ¼ 0.001), and equally high satisfaction rate, acceptability and improved quality of life 1 year after treatment for both groups. These results were sustained at 2-year follow-up. At 5-year follow-up [36 ] both techniques achieved significant and comparable improvements in menstrual symptoms, and healthrelated quality of life. While high rates of satisfaction with treatment and acceptability of treatment were achieved by TCRE, these were significantly lower than following MEA. These long-term data, when combined with the trials' operative findings and known costs of both procedures, led the authors to conclude that MEA is a more effective and efficient treatment for heavy menstrual loss than TCRE.
Complications of second-generation ablation devices
Minor immediate postoperative complications are common among second-generation ablation devices, and include pelvic pain, endometritis, urinary tract infection, nausea and vomiting, haematometra and pelvic inflammation. To date, these and other minor complications have been reported in the medical literature. The frequency of their occurrence and, in particular, the more serious complications remain difficult to establish, however. Several reports have attempted to address this deficiency. Rogerson and Duffy [37] conducted a European survey of complications among surgeons undertaking Thermachoice ablation and reported a 0.24% incidence of nonmachine-related operative complication, 3.92% postoperative complications rate and emergency additional surgery rate in 0.04% of 5859 cases. These figures compared very favourably with the MISTLETOE study for first-generation ablation devices. Others [38] searched the medical literature, the Cochrane database, MAUDE database of medical device adverse events submitted to the US Food and Drug Administration (website: http://www.fda.gov/cdrh/ maude.html) and relevant textbooks. The authors relied on the manufacturers' estimated number of procedures in the USA for each device, and calculated complication rates of 0.56, 1.2, 1, and 0.96 per 1000 for Thermachoice, NovaSure, Her Option and HydroThermAblator, respectively. Reported serious complications included sepsis, adnexal/uterine necrosis, lower genital tract thermal injury and one death. Many of these resulted from non compliance with manufacturers' instructions and other avoidable factors. A 2005 update of a Cochrane Database of Systematic Review [39 ] concluded that equipment failure, nausea and vomiting, and uterine cramping were more likely with second-generation ablation devices, but these were less likely to be associated with fluid overload, uterine perforation, cervical lacerations and haematometra than conventional ablation and resection techniques. Overall, they compared favourably with TCRE. Other poorly defined risks include the incidence of endometrial cancer [40] and pregnancies after second-generation ablation techniques [41] . The above reports highlight the significant deficiency in structured data gathering. There is an urgent need to establish definitively the true incidence of such complications as reported for firstgeneration devices in the MISTLETOE study [42] .
Comparisons between techniques
Few studies have compared second-generation ablation techniques with each other. Bongers et al. [43] compared Novasure with Thermachoice 1 in a randomized controlled study, and reported significantly higher amenorrhoea and satisfaction rates with the bipolar device at 1-year follow-up. Another group [44 ] reported that both methods significantly improved health-related quality of life questionnaires and that there was no difference between the two groups despite the menstrual and satisfaction data. A comparison between Novasure and Thermachoice [45] reported significantly less intra and postoperative pain with Novasure; however, all women undergoing Thermachoice had 3-min dilatation and suction curettage, which might have contributed to the pain scores.
Abbott et al. [31] , in a randomized controlled trial of Novasure and Cavaterm, reported significantly lower pain scores for the Novasure device at 4 h after surgery and higher amenorrhoea rates at 12 months. Patient satisfaction and quality of life questionnaires were comparable between the groups at 12 months follow-up, but Novasure had 16% repeat procedures compared with 0% for Cavaterm. Another group [46] compared clinical outcomes and quality of life questionnaires between three second-generation techniques and laser ablation in a descriptive cohort study. The authors reported nonsignificant differences between the combined amenorrhoea and hypomenorrhoea rates and the quality of life scores at 12 months after treatment. A recent systematic review [47 ] assessed MEA with Thermachoice 1, and concluded that as no head-to-head trials have been performed between the two techniques, there was not enough evidence of differences in terms of clinical effectiveness to recommend one over another. The reader may also seek additional information on first-generation ablation devices from a recent review on the subject [48 ] .
Implications for clinical practice
Menstrual problems are among the most common reasons for specialist referrals and account for a third of gynaecological outpatient workload with an expanding multitude of treatment options [49 ] . The choice of treatment should be taken jointly by the woman and her clinician after taking all factors into consideration. In England, the trends in the number of hysterectomies performed for menorrhagia between 1989 and 2002/3 showed a substantial fall to just over one-third (36%) of the number of a decade earlier, most notably from 1995 [50 ] . This fall is not due to endometrial ablation alone, however, and other factors such as better patient education, the introduction of clinical guidelines and the use of the MIRENA intrauterine system for the treatment of menorrhagia, although only for such purpose in 2001, may all have added to this decline. Interestingly, the introduction of first-generation techniques in the 1980s did not appear to result in a similar downward trend.
Often, the question 'Which device should I use?' is asked. Each device has its relative strengths and weaknesses, and no single device can be preferred over another in all circumstances. The evidence presented above suggests that clinicians should consider the safety and effectiveness figures, applicability to the outpatient environment, and evidence of quality of life improvement applied on an individualized basis after full discussion with the patient and taking her preferences into account as well as surgical skill available at any institution.
Implications for the health service
An excellent attempt to apply a cost-utility economic model to microwave and thermal balloon endometrial ablation for heavy menstrual bleeding and compare their cost-effectiveness [51] concluded that despite limitations in available data, the evidence suggested that secondgeneration techniques were likely to be more cost-effective than first-generation techniques in most cases. Hysterectomy, where a woman finds this option acceptable, continues to be a very cost-effective procedure compared with all endometrial ablation methods.
The implications for the UK National Health Service will depend on the number of women suitable for these techniques, and the uptake rates as influenced by patients' choice and clinicians' preference. Furthermore, the full economic impact of introducing these techniques into the outpatient setting will only be determined by hypothesis-driven, properly designed and powered randomized controlled trials [52 ] . A comprehensive review of thermal balloon ablation and MEA devices and their clinical and health service impact published by the National Institute of Clinical Excellence estimated that if all hysterectomies were replaced by second-generation ablation techniques, the annual cost saving would be in excess of £32 million, and would be less if first and second-generation techniques were used [53 ] . It was also argued that such savings are, however, unlikely to be realized financially as (1) the estimates represent amounts of resources that would remain within the system, but nevertheless be redeployed, and (2) are based on average and fixed costs that would not be saved but could be available for other purposes.
Conclusion
More evidence has accumulated in the past few years on the long-term efficacy and suitability of second-generation ablation devices in the outpatient and community settings. Evidence is also emerging that improvement in the quality of life is a more important endpoint to women than the occurrence of amenorrhoea. Such findings have informed the debate on the role of these techniques in clinical practice and enabled health economists to assess their true impact on the health service. There are, however, only very few studies comparing these techniques with each other and, equally, more effort should be made to collect reliable data on the frequency of treatmentassociated complications. These deficiencies would only be answered by properly designed and implemented prospective studies.
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